Tackling pseudomonas aeruginosa virulence by a hydroxamic acid-absed LasB inhibitor by Kany, Andreas M. et al.
\  
 
 
 
 
 
Kany, A. M., Sikandar, A., Yahiaoui, S., Haupenthal, J., Walter, I., 
Empting, M., Köhnke, J. and Hartmann, R. W. (2018) Tackling 
pseudomonas aeruginosa virulence by a hydroxamic acid-absed LasB 
inhibitor. ACS Chemical Biology, 13(9), pp. 2449-2455. (doi: 
10.1021/acschembio.8b00257) 
 
The material cannot be used for any other purpose without further 
permission of the publisher and is for private use only. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it.  
 
 
http://eprints.gla.ac.uk/224173/  
 
 
 
 
 
 
   Deposited on 16 November 2020 
 
 
 
 
 
Enlighten – Research publications by members of the University of       
           Glasgow 
http://eprints.gla.ac.uk  
 
Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based 
LasB Inhibitor 
 
 
Andreas M. Kany†, Asfandyar Sikandar‡, Samir Yahiaoui†, Jörg Haupenthal†, Martin Empting†, Jesko 
Köhnke‡, Rolf W. Hartmann*,†,§ 
† Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Department of Drug Design and 
Optimization, Campus E8.1, 66123, Saarbrücken, Germany 
‡ Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Workgroup Structural Biology of 
Biosynthetic Enzymes, Campus E8.1, 66123, Saarbrücken, Germany 
§ Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus 
E8.1, 66123 Saarbrücken, Germany 
* Rolf.Hartmann@helmholtz-hzi.de 
 
ABSTRACT 
In search of novel antibiotics to combat the challenging spread of resistant pathogens, bacterial proteases 
represent promising targets for pathoblocker development. A common motif for protease inhibitors is 
the hydroxamic acid function, yet this group has often been related to unspecific inhibition of various 
metalloproteases. In this work, the inhibition of LasB, a harmful zinc metalloprotease secreted by 
Pseudomonas aeruginosa, through a hydroxamate derivative is described. The present inhibitor was 
developed based on a recently reported, highly selective thiol scaffold. Using X-ray crystallography, the 
unprecedented maintenance of the high selectivity against a range of human matrix-metalloproteases 
could be attributed to a distinct binding mode sparing the S1´ pocket. The inhibitor was shown to restore 
the effect of the antimicrobial peptide LL-37, to reduce the formation of P. aeruginosa biofilm and, for 
the first time for a LasB inhibitor, the release of extracellular DNA. Hence, it is capable of disrupting 
several important bacterial resistance mechanisms. These results highlight the potential of protease 
inhibitors to fight bacterial infections and point out the possibility to achieve selective inhibition even 
with a strong zinc anchor. 
 
 
Proteases have proven to be attractive targets for the treatment of various diseases, including infections.1 
While antiviral protease inhibitors are in clinical use for the treatment of e.g. HIV or HCV, no bacterial 
protease inhibitors have been approved as anti-infective drugs yet.2,3 However, in order to combat the 
spread of antibiotic resistance, new antibacterial agents with novel modes of action are urgently 
needed.4–6 This applies especially for Gram-negative pathogens which are challenging to treat as their 
cell wall is difficult to permeate.7 The development of pathoblockers which target bacterial virulence 
rather than killing bacteria is of growing interest in anti-infective drug discovery, due to the reduced 
selection pressure such a strategy is supposed to have.8–12 In this context, bacterial proteases represent 
attractive targets.2,3,13 Notably, the only FDA-approved anti-virulence drugs are immunoglobulins that 
target secreted virulence factors, highlighting the potential of extracellular targets to circumvent cell 
wall permeation problems.8 The highly problematic Gram-negative pathogen Pseudomonas aeruginosa 
has been assigned critical priority by the WHO14 and urgently requires novel treatment options because 
of increasing resistance.15,16 P. aeruginosa is i.a. responsible for fatal lung infections in cystic fibrosis 
patients.17 Among its numerous virulence factors representing potential drug targets,12,16,18–20 the zinc-
metalloprotease elastase (LasB) is of specific interest, given its extracellular location.21 LasB 
substantially contributes to disease progression in P. aeruginosa infected individuals by facilitating host 
invasion and immune evasion.22 It was for example found to degrade and thereby inactivate the 
endogenous antimicrobial peptide (AMP) LL-37.23 Furthermore, LasB was reported to be involved in 
the formation of P. aeruginosa biofilms either by periplasmic activation of nucleoside diphosphate 
kinase (NDK) required for alginate synthesis24, or by upregulation of rhamnolipids.25 The aggregation 
of bacteria in the biofilm matrix seriously impedes successful antibiotic treatment and blocks host 
defense mechanisms.26,27   
Several thiol-based inhibitors with promising activity on LasB have been described.28–32 A class of 
N-aryl mercaptoacetamides turned out to be particularly attractive since these thiols display high 
selectivity against a range of human matrix metalloproteinases (MMPs).32,33 Thiol-containing 
compounds are in clinical use for the treatment of various diseases.34–36 However, a disadvantage of this 
class compared to other zinc-chelating inhibitors is the possible oxidation to the respective disulfides, 
resulting in inactivation of the compounds.37 
In this study, we describe the synthetic replacement of the sulfhydryl function of LasB inhibitor 132 (IC50 
6.6 ± 0.3 µM, Figure 1) by zinc-binding groups insensitive to oxidation. Among the compounds tested, 
a hydroxamic acid derivative was found to inhibit LasB in the low micromolar range as well. 
Hydroxamates have been reported as LasB inhibitors, but the described compounds lack selectivity 
against human MMPs.38,39  In contrast, the inhibitor described in this work maintained the remarkable 
selectivity of thiol 1 against human MMPs, despite a binding mode equivalent to described 
hydroxamate-MMP complexes. The new compound was further able to reduce biofilm formation and 
eDNA release by P. aeruginosa and to restore the antimicrobial effect of LL-37. 
 
Figure 1. Structures of lead LasB inhibitor 1 and compounds 3–8 synthesized in this article. 
 
RESULTS AND DISCUSSION 
Synthesis of novel compounds 3–8. 
Among the variety of chemically diverse zinc binding groups in literature,40 we focused on hydroxyl, 
carboxyl and hydroxamate functions. By introducing these relatively small zinc chelating groups, drastic 
changes in the size of the thiol function of 1 were avoided in order to allow the inhibitor backbone to 
preserve the previously observed binding mode.32 Carboxylic acid derivatives 3, 4 and 6 were obtained 
either by reacting aniline 2 with succinic/maleic anhydride or via hydrolysis of methylester intermediate 
5. Similarly, 7 was synthesized by reacting 5 with hydroxylamine (Scheme 1, A-B). As an isosteric 
modification we further synthesized the alcohol derivative of 1, compound 8, using glycolic acid in a 
neat reaction (Scheme 1, C).  
 
Scheme 1. Reagents and conditions: (a) succinic anhydride, dioxane, 70 °C, 6 h, (b) maleic anhydride, dioxane, 70 °C, 6 h; (c) 
methyl malonyl chloride, Et3N, DCM, RT, 4 h; (d) NaOH, THF, RT, 24 h; (e) H2NOH, DIPEA, MeOH, 8 h reflux, 16 h RT; 
(f) glycolic acid, 130°C, 24 h 
 
Identification of compound 7 as a potent LasB inhibitor 
Using a FRET-based inhibition assay41 it turned out that replacement of the thiol function of 1 by a 
hydroxy group led to a complete loss of activity when tested at 600 µM (8). Compounds bearing a 
carboxylic acid in γ- (3,4) or in β-position (6) to the carbonyl group were also inactive. Contrary to that, 
the β-hydroxamic acid derivative 7 displayed an IC50 of 17.4 ± 0.8 µM.  
 
Binding Mode of 7 to LasB. 
In order to rationalize whether the minor difference in activity compared to 1 was due to a different 
binding mode, the X-ray co-crystal structure of the LasB-7 complex was solved. The complex 
crystallized in space group P212121 and crystals diffracted to 2.1 Å resolution (Figure 2, A). The structure 
was solved by molecular replacement using the published LasB structure (PDB ID 1EZM) as a search 
model. Full details of the data collection and refinement statistics can be found in Supplementary Table 
1. Hydroxamate 7 was found to be orientated toward the primed binding site of the protease. As 
expected, the active site zinc atom is coordinated by both the carbonyl oxygen and the hydroxamide 
oxygen of 7, leading to a distorted trigonal-bipyramidal geometry. The carbonyl oxygen further 
undergoes a weaker interaction with His223 (3.5 Å). Additionally, the hydroxamide oxygen forms a 
hydrogen bond with the adjacent Glu141 (2.5 Å), while the amide nitrogen interacts with the carbonyl 
group of Ala113 (3.0 Å). These observations are in excellent accordance with the reported binding of 
hydroxamate functions to MMP-7,42 MMP-343 or to thermolysin.44 Inhibitor binding to thermolysin-like 
proteases like LasB was described to lead to a closure of the binding pocket due to hinge-bending 
motion.45 Intriguingly, thiol 1 has recently been discovered by us to keep the active site cleft in an open 
conformation due to the unexpected binding of two molecules to the primed binding site (Supplementary 
Figure1).32 In contrast, only one molecule of the hydroxamate binds to the protease, which undergoes 
the characteristic hinge-bending. Unlike the zinc-chelating thiol, the hydroxamate directly interacts with 
the edge strand via a hydrogen bond with the main chain oxygen of Ala113. This interaction presumably 
promotes closure of the active site cleft, which is hampered in case of thiol 1 by the second molecule 
interacting with Asn112. Due to the twisted orientation of the aromatic core of 7 compared to 1, a 
previously observed bidentate hydrogen bond with Arg198 in the S1′ binding site is not possible. This 
observation could explain the slightly weaker activity of the hydroxamate compared to the thiol. 
 
Figure 2. (A) Structure of LasB in complex with 7. Cartoon representations of LasB (cyan) in complex with 7 (black). The 
difference electron density (Fo-Fc) contoured to 3σ with phases calculated from a model that was refined in the absence of 7 is 
shown as a blue isomesh. The active-site zinc ion is shown as a grey, calcium ion as a green sphere. Residues involved in 
binding of 7 are shown as sticks, their interactions depicted as yellow dashed lines. Zinc-liganding distances are 2.1 Å (OH) 
and 2.4 Å (NH). (B) Overlay of LasB (cyan) in complex with 7 (grey) and MMP-3/-7 (green) occupied by hydroxamate 
inhibitors 9 and 10 (brown, PDB codes 4G9L/1MMQ). Zinc ligands are highlighted. 
 
Selectivity against MMPs. 
Strong zinc chelating groups like hydroxamic acids can be the reason for poor selectivity against further 
metalloproteases, when compound binding is driven more by the chelating moiety than by the rest of 
the molecule.46 In fact, the lack of selectivity against MMP anti-targets has been one reason for the 
failure of various hydroxamate-based MMP inhibitors in clinical trials.47,48 Considering the high 
similarity in zinc chelation by 7 and the hydroxamates in MMP-3 or MMP-7, it was investigated whether 
the previously demonstrated selectivity of N-aryl mercaptoacetamides toward six human MMPs32,33 
could be maintained. Fortunately, 7 did not inhibit these MMPs comprising members with differing 
depth of the S1′ binding site49 including MMP-3 and -7 (Table 1). By contrast, the unselective inhibitor 
Batimastat50 (Supplementary FigureS2) inhibited  all tested enzymes in the low nanomolar range. 
Table 1. Residual activity of six MMPs in presence of 100 µM 7 and IC50 values of Batimastat33; Means and SD of at least 
three independent measurements are displayed. 
 
7 Batimastat 
Residual activity at 
100 µM [%] 
IC50 [nM] 
MMP-1 91 ± 9 2.2 ± 0.1 
MMP-2 87 ± 3 1.8 ± 0.1 
MMP-3 84 ± 5 5.6 ± 0.9 
MMP-7 98 ± 3 7.0 ± 0.2 
MMP-8 73 ± 6 0.7 ± 0.2 
MMP-14 98 ± 4 2.8 ± 0.2 
 
This of course prompted the question why, despite comparable interactions of the hydroxamate function, 
LasB was inhibited but not MMP–7. Logically, the selectivity might be related to differences in the 
positioning of the inhibitor backbone in the pocket. In order to investigate this, published X-ray 
structures of MMPs in complex with hydroxamates were overlaid with the LasB-7 complex. The shallow 
S1´ pocket of MMP-7 is occupied by an isobutyl moiety of inhibitor 942 and the deep S1´ pocket of 
MMP-3 by an aromatic core of inhibitor 1043 (for inhibitor structures see Supplementary FigureS3). In 
contrast, the core of 7 does not bind to the respective pocket of LasB (Figure 2, B). The  ability to bind 
the S1´ pocket of the respective MMP is a common feature of reported hydroxamate-based MMP 
inhibitors, which can also be the cause for a lack of selectivity.46,51 Consequently, the high selectivity 
against various MMPs with differing depth of the S1´ binding pocket could be explained by an inability 
of 7 to bind to this site of the protease.Cytotoxicity Assays. 
In addition to selectivity, it was also investigated whether the cytotoxicity of 7 toward human cell lines 
was as low as described for thiol 1.32 This was of specific interest since cytotoxic properties are a known 
drawback of hydroxamates.52 Notably, 7 had only low effects on the viability of HEP G2 cells, 
comparable to thiol 1 and rifampicin (Figure 3). The effect on HEK293 cells was more pronounced at  
the tested concentrations.  
 
Figure 3. Cytotoxicity of 1, 7 and two reference compounds toward HEP G2 and HEK293 cells (Values for 1 are taken from32) 
 
Selectivity against HDACs. 
Considering the cytotoxic effects of 7 against HEP G2 cells, it was investigated whether this observation 
could be related to inhibition of histone deacetylases (HDACs).53 These zinc-dependent enzymes are 
involved in the epigenetic regulation of cell proliferation and differentiation.54 Given that HDACs are 
known to be inhibited by hydroxamic acids like vorinostat or trichostatin A,55 assessing a potential 
inhibitory effect of hydroxamate 7 was of special interest. Figure 4 shows that 7 does not exert any 
inhibitory effect on HDAC3 and HDAC8, while these enzymes are efficiently inhibited by the positive 
control trichostatin A (Supplementary Figure 2). The observed selectivity against these additional 
antitargets could be explained by the absence of a long linker separating the zinc chelating function from 
the aromatic core, as it is typical for hydroxamate-based HDAC inhibitors.52,56  
 
Figure 4. Residual activity of selected HDAC enzymes in presence of 100 µM 7. 
 
Restoration of LL-37 antibacterial activity against P. aeruginosa PA14. 
LL-37 is an α-helical human cathelicidin peptide, which shows increased prevalence in cystic fibrosis 
patients.57 Its effectiveness against P. aeruginosa is considerably reduced as it is susceptible toward 
cleavage by LasB.23 In order to assess a potential restoration effect of 7 on the activity of LL-37, a 
bacterial growth assay with PA14 and LL-37 in presence/absence of 7 was performed (Figure 5). The 
antibacterial effect of LL-37 alone was only minor at 25 µg/mL (p = 0.0211). However, when combined 
with the LasB inhibitor, it recovered its ability to reduce bacterial growth in a dose-dependent way. 
Significant reduction of the OD600 was observed starting from a hydroxamate concentration of 62.5 µM 
(p = 0.0047). At high concentrations, 7 itself slightly inhibited PA14 growth, yet to a much lower extent 
than in combination with LL-37 (p = 0.0255 at 250 µM 7). These findings highlight the potential of 
LasB inhibitor 7 to restore a host defense mechanism which is otherwise hampered by LasB. 
 
Figure 5. Growth of PA14 cultures incubated with 7 in absence (blue) and presence (red) of 25 µg/mL LL-37. Means and SD 
of three independent measurements are depicted. * = p < 0.05, ** = p < 0.01, **** = p < 0.0001 
 
Biofilm volume and eDNA reduction 
The biofilm matrix, a key element of P. aeruginosa resistance,26 is composed of extracellular 
polysaccharides, lipids, proteins and, importantly, extracellular DNA (eDNA).58,59 Inhibition of LasB 
was shown to inhibit biofilm formation.28 Therefore, it was of great interest to investigate whether 
treatment of PA14 cultures with 7 would result in reduced biofilm formation as well. Indeed, the 
hydroxamate caused a concentration-dependent reduction of eDNA release (Figure 6, A) and of the 
overall biofilm volume (Figure 6, B). Since significant inhibition was observed at concentrations lower 
than 250 µM, these effects can be attributed to the on-target activity of the compound and are not due 
to a reduction of bacterial growth or lysis of cells. Hence, LasB inhibitor 7 has demonstrated important 
pathoblocker activity. It is able to interfere with crucial factors leading to bacterial resistance of P. 
aeruginosa toward antibiotics and host defense molecules.27,60 To the best of our knowledge, no direct 
correlation between LasB inhibition and a reduction of eDNA release has been reported to date. 
Regarding the two mechanisms discussed in literature, the reduced biofilm formation is either due to a 
reduced NDK-mediated alginate synthesis,24 or rhamolipid-mediated.25 Which of these mechanisms 
inhibitor 7 interferes with cannot be concluded. Yet, these findings could hint at the capacity of 7 to 
permeate at least the outer membrane of the Gram-negative cell wall, as far as an inhibition of 
periplasmic NDK24 is concerned. 
 
Figure 6. Reduction of eDNA release by treatment of PA14 cultures with 7. (A) Reduction of overall PA14 biofilm volume by 
7. (B) Columns represent mean and SD of at least four independent measurements. ** = p < 0.01, **** = p < 0.0001 
 
CONCLUSION 
Based on our recent findings that N-aryl mercaptoacetamides are promising highly selective inhibitors 
of the virulence factor LasB from P. aeruginosa, the lead inhibitor was modified by changing the zinc-
chelating moiety to a hydroxamate. Using X-ray crystallography, it was shown that similar to the thiol 
analogue 1, hydroxamate 7 occupied the primed binding site. Contrary to our recent observations for 1, 
only one inhibitor molecule was bound to the protease, which could undergo the characteristic hinge-
bending motion resulting in a closed conformation of the enzyme. This was attributed to the ability of 
the inhibitor to interact with catalytic zinc and the edge strand alike. Despite the high similarity of zinc 
binding to hydroxamates inhibiting MMP-7, inhibitor 7 was unexpectedly able to maintain the 
remarkable selectivity of 1 toward a range of MMPs. This could be rationalized by the fact that the S1´ 
pocket was not occupied by 7, unlike observed for MMP inhibitors. These findings show that despite 
the selectivity issues related to hydroxamic acids, selectivity can indeed be achieved by sparing the S1´ 
pocket. Since cytotoxic effects toward mammalian cell lines were observed, there will be a special focus 
on cytotoxicity during future compound optimization.  Below an antibacterial concentration of 250 µM, 
LasB was efficiently inhibited in vitro. This inhibition could be translated into more complex, cellular 
assays, highlighting this compound as a promising anti-virulence agent. After reduction of their 
pathogenicity by such an agent, bacteria are supposed be cleared by host defense mechanisms or with 
the help of conventional antibiotics.10,11 In this context, our results highlight a direct restoration effect 
of the antibacterial activity of the host defense peptide AMP LL-37 in vitro. Indirectly, the activity of 
host defense mechanisms might be further improved by the inhibition of biofilm formation and eDNA 
release also observed for 7. The same holds true for the effectiveness of conventional antibiotics, which 
is seriously hampered by bacterial biofilms. Overall, these findings show hydroxamate 7 to be an 
interesting lead, which could pave the way for the rational development of selective protease inhibitors 
as potential new antibiotics. 
 
METHODS. 
Chemistry. All reagents were used from commercial suppliers without further purification. Procedures 
were not optimized regarding yield. NMR spectra were recorded on a Bruker Fourier 300 (300 MHz) 
spectrometer. Chemical shifts are given in parts per million (ppm) and referenced against the residual 
proton, 1H, or carbon, 13C, resonances of the >99% deuterated solvents as internal reference. Coupling 
constants (J) are given in Hertz. Data are reported as follows: chemical shift, multiplicity (s = singlet, 
d = doublet, t = triplet, m = multiplet, br = broad and combinations of these) coupling constants and 
integration. Mass spectrometry was performed on a SpectraSystems-MSQ LCMS system (Thermo 
Fisher). Flash chromatography was performed on silica gel 60 M, 0.04–0.063 mm (Machery-Nagel) or 
using the automated flash chromatography system CombiFlash Rf+ (Teledyne Isco) equipped with 
RediSepRf silica columns (Axel Semrau) or Chromabond Flash C18 columns (Macherey-Nagel). Purity 
of compounds synthesized by us was determined by LCMS using the area percentage method on the UV 
trace recorded at a wavelength of 254 nm and found to be >95%.  
Expression and Purification of LasB. LasB was expressed and purified as described previously.32 
In vitro Inhibition Assays. The LasB in vitro inhibition assay and the MMP assay were performed as 
described previously.32 
HDAC Inhibition Assay. HDAC3 and HDAC8 inhibitor screening kits were purchased from Sigma-
Aldrich. The assay was performed according to the guidelines of the manufacturer. Fluorescence signals 
were measured in a CLARIOstar plate reader (BMG Labtech). 
Cytotoxicity assays. Hep G2 or HEK293 cells (2 x 105 cells per well) were seeded in 24-well, flat-
bottomed plates. Culturing of cells, incubations and OD measurements were performed as described 
previously61 with small modifications. 24 h after seeding the cells the incubation was started by the 
addition of compounds in a final DMSO concentration of 1 %. The living cell mass was determined 
after 48 h. At least three independent measurements were performed for each compound. 
X-ray Crystallography and image preparation. LasB was concentrated to 10–12 mg mL–1 and mixed 
with inhibitor 7 at a final concentration of 1 mM. Complex crystals were grown by the sitting drop 
method using a reservoir solution containing 1.8 M AMSO4 and 0.1 M Tris-Cl, pH 8.8. Crystals were 
cryoprotected in glycerol and diffraction data was collected from single crystals at 100 K at beamline 
ID29 (ESRF) at a wavelength of 1.738 Å. Data was processed using Xia262 and the structure solved 
using PHASER863 molecular replacement with Pseudomonas aeruginosa LasB (PAE, PDB ID 1EZM) 
as a search model. The solution was manually rebuilt with COOT64 and refined using PHENIX65 and 
Refmac566. The final refined structure of LasB in complex with compound 7 was deposited in the Protein 
Data Bank (PDB) as entry 6FZX. Structural superimposition of complex structures of human MMPs 
(1MMQ and 4G9L) and LasB (6FZX) was achieved through alignment of residues 201–205 of 4G9L 
(corresponds to residues 140–144 of 1MMQ) using the align atoms algorithm of YASARA structure 
(YASARA Biosciences GmbH).67 Image was rendered using PovRay (http://www.povray.org/). 
Bacterial growth assay. The assay was performed in 96 well plates (Greiner) with a final volume of 
200 µL. LL-37 was purchased from AnaSpec (Fremont) and diluted to a final concentration of 25 µg 
mL–1 from 125 µg mL–1 stocks in 18MΩ H2O. Prior to culture addition 7 was serially diluted in DMSO. 
A pre-culture of PA14 was adjusted to the final start OD600 0.02 in lysogeny broth medium. All samples 
contained 1% DMSO and 40% of 18MΩ H2O. OD600 was measured using a FLUOstar Omega (BMG 
Labtech) after inoculation and after incubation for 16.5 h at 37°C with 200 rpm. Given OD600 values 
were obtained after subtraction of the respective start OD600 and represent three independent 
measurements with at least two replicates each. One-way ANOVA was performed using GraphPad 
Prism 6 software. 
Biofilm and eDNA assays. The assays were performed as described previously.68 
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